Comments
Eris Lifesciences Ltd has acquired the trademarks for anti-diabetic drug Zomelis for vildagliptin-based formulations, and its associated trademarks, from Switzerland-based Novartis AG for $13 million (approx ₹93 crore).
Zomelis is used in the treatment of type-2 diabetes and comes under a new class of anti-diabetic drugs known as DPP 4 inhibitors. Ahmedabad-based Eris will start selling the product from December 10 in the Indian market.
“The acquisition of Zomelis will help us strengthen our position in the diabetes care market in India,” said Eris CMD Amit Bakshi. “Zomelis is a strong brand amongst the super specialty prescriptions and has been promoted for close to 10 years. Our inorganic growth strategy continues as we explore good opportunities to strengthen our product offering for patients.”
This is the first innovator pharmaceutical product trademark acquisition by Eris, which claims to be among the leading players in the anti-diabetes drugs segment in India.
In December 2017, it had acquired the branded generics business portfolio of Strides Shasun for about ₹500 crore. Its past acquisitions include the UTH, Kinedex and Amay Pharma trademarks to make an entry into the nutraceuticals, women’s health and IVF segments.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.